Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Medbanks
思派健康科技

Sipai Health Technology Co., Ltd.
思派健康科技有限公司

(A company incorporated in the Cayman Islands with limited liability)
(Stock Code: 0314)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT

Reference is made to the Company's 2025 Annual Report published on April 24, 2026. In addition to the information provided in the foregoing report, the Board would like to provide further information in relation to its investment activities. Unless otherwise defined, capitalized terms shall have the same meaning as used in the 2025 Annual Report.

For the year ended December 31, 2025, the Company has financial assets at FVTPL of approximately RMB460.1 million and the Company experienced a moderate gain of RMB15.5 million on its wealth management products during the financial year primarily as a result of interest or similar income generated from the wealth management products. The Group's financial assets consist exclusively of structured deposits, monetary funds and onshore wealth management products issued by licensed bank in the PRC. Currently, the Company makes investments prudently, focusing primarily on wealth management investment that are low-risk and capital preserving in nature, all investment transactions are approved in accordance with the Company's internal control policies by the Group's management.

INVESTMENT POLICY AND OBJECTIVES

The Company has a set of risk management measures and internal protocols to ensure that the investments are assessed, and that risks associated with wealth management product subscription are within a reasonable level of fluctuation. This typically means that the Company would target prudent treasury management opportunities offering modest return while being principal preservative in nature. While the Group also considers investment in other business ventures and may participate in equity investments or other investment opportunities, the Company will analyze the inherent risks and the potential benefits (including financial return as well as any other benefit that the investment could present).

RISK MANAGEMENT, CONTROL MEASURES AND OVERSIGHT

The Company has a multi-layer approval mechanism involving various divisions including the treasury department and the finance department. Ordinarily, wealth management transactions under threshold of RMB50 million are ultimately approved by the finance department. For other investment transactions exceeding RMB50 million, approval of the finance department and the chief executive officer of the Company, and is also subject to the applicable Listing Rules requirements for notifiable transaction under Chapter 14 of the Listing Rules the Company may also consult external advisers during the approval process if it regards such consultation as necessary, with an aim to ensure that the risks relating to the investments made are manageable and that the investments are made in the interest of the Company and the Shareholders as a whole.

The Group manages liquidity risk through cash flow forecasting, liquidity monitoring, and managing the maturity or redemption timing of its wealth management products. The objective is to ensure that sufficient financial resources are available to meet the Group's operational needs, capital commitments, and strategic funding requirements. The Group's cash and liquid investments, liquidity profile and cash flow forecasts are reported to the Board, enabling the Board to exercise oversight of liquidity adequacy and treasury investment performance.

ALIGNMENT WITH CORPORATE STRATEGY

The Group's investment strategy is designed to complement and support its corporate strategy and long term business goals. The Company seeks to make treasury management investments will enable the Company to maximize its capital efficiency. The Group's prudent treasury investment strategy is aligned with its overall corporate strategy, risk management objectives, and long-term business development plans.

Save for the supplemental information set forth herein, all other information in the 2025 Annual Report remains unchanged.

By Order of the Board
Sipai Health Technology Co., Ltd.
MA Xuguang
Chairman of the Board and Executive Director

Hong Kong, November 23, 2026

As at the date of this announcement, the Board comprises Mr. MA Xuguang and Mr. LI Ji as executive directors, Mr. YAO Leiwen as non-executive director, Mr. FAN Xin, Mr. HE Haijian and Ms. HUANG Bei as independent non-executive directors.